These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 23675940)

  • 21. In Vitro - in Vivo Extrapolation of Hepatic Clearance in Preclinical Species.
    Tess DA; Ryu S; Di L
    Pharm Res; 2022 Jul; 39(7):1615-1632. PubMed ID: 35257289
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The glucuronidation of R- and S-lorazepam: human liver microsomal kinetics, UDP-glucuronosyltransferase enzyme selectivity, and inhibition by drugs.
    Uchaipichat V; Suthisisang C; Miners JO
    Drug Metab Dispos; 2013 Jun; 41(6):1273-84. PubMed ID: 23554428
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Extrapolation of the Hepatic Clearance of Drugs in the Absence of Albumin In Vitro to That in the Presence of Albumin In Vivo: Comparative Assessement of 2 Extrapolation Models Based on the Albumin-Mediated Hepatic Uptake Theory and Limitations and Mechanistic Insights.
    Poulin P; Haddad S
    J Pharm Sci; 2018 Jul; 107(7):1791-1797. PubMed ID: 29567347
    [TBL] [Abstract][Full Text] [Related]  

  • 24. New IVIVE method for the prediction of total human clearance and relative elimination pathway contributions from in vitro hepatocyte and microsome data.
    Riede J; Poller B; Umehara K; Huwyler J; Camenisch G
    Eur J Pharm Sci; 2016 Apr; 86():96-102. PubMed ID: 26948853
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Drug Design and Success of Prospective Mouse In Vitro-In Vivo Extrapolation (IVIVE) for Predictions of Plasma Clearance (CL
    Manevski N; Umehara K; Parrott N
    Mol Pharm; 2023 Jul; 20(7):3438-3459. PubMed ID: 37235687
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Strategies to improve the prediction accuracy of hepatic intrinsic clearance of three antidiabetic drugs: Application of the extended clearance concept and consideration of the effect of albumin on CYP2C metabolism and OATP1B-mediated hepatic uptake.
    Fujino R; Hashizume K; Aoyama S; Maeda K; Ito K; Toshimoto K; Lee W; Ninomiya SI; Sugiyama Y
    Eur J Pharm Sci; 2018 Dec; 125():181-192. PubMed ID: 30287410
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The prediction of drug-glucuronidation parameters in humans: UDP-glucuronosyltransferase enzyme-selective substrate and inhibitor probes for reaction phenotyping and in vitro-in vivo extrapolation of drug clearance and drug-drug interaction potential.
    Miners JO; Mackenzie PI; Knights KM
    Drug Metab Rev; 2010 Feb; 42(1):196-208. PubMed ID: 19795925
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Does Addition of Protein to Hepatocyte or Microsomal In Vitro Incubations Provide a Useful Improvement in In Vitro-In Vivo Extrapolation Predictability?
    Kameyama T; Sodhi JK; Benet LZ
    Drug Metab Dispos; 2022 Apr; 50(4):401-412. PubMed ID: 35086847
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vitro inhibitory effects of major bioactive constituents of Andrographis paniculata, Curcuma longa and Silybum marianum on human liver microsomal morphine glucuronidation: A prediction of potential herb-drug interactions arising from andrographolide, curcumin and silybin inhibition in humans.
    Uchaipichat V
    Drug Metab Pharmacokinet; 2018 Feb; 33(1):67-76. PubMed ID: 29241692
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Characterization of 2-[[4-[[2-(1H-tetrazol-5-ylmethyl)phenyl]methoxy]methyl]quinoline N-glucuronidation by in vitro and in vivo approaches.
    Stevens JC; Fayer JL; Cassidy KC
    Drug Metab Dispos; 2001 Mar; 29(3):289-95. PubMed ID: 11181497
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prediction of drug clearance by glucuronidation from in vitro data: use of combined cytochrome P450 and UDP-glucuronosyltransferase cofactors in alamethicin-activated human liver microsomes.
    Kilford PJ; Stringer R; Sohal B; Houston JB; Galetin A
    Drug Metab Dispos; 2009 Jan; 37(1):82-9. PubMed ID: 18832476
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Altered AZT (3'-azido-3'-deoxythymidine) glucuronidation kinetics in liver microsomes as an explanation for underprediction of in vivo clearance: comparison to hepatocytes and effect of incubation environment.
    Engtrakul JJ; Foti RS; Strelevitz TJ; Fisher MB
    Drug Metab Dispos; 2005 Nov; 33(11):1621-7. PubMed ID: 16049128
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of the Predictability of Human Hepatic Clearance for Organic Anion Transporting Polypeptide Substrate Drugs Between Different In Vitro-In Vivo Extrapolation Approaches.
    Izumi S; Nozaki Y; Komori T; Takenaka O; Maeda K; Kusuhara H; Sugiyama Y
    J Pharm Sci; 2017 Sep; 106(9):2678-2687. PubMed ID: 28238896
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Generating an in vitro-in vivo correlation for metabolism and liver enrichment of a hepatitis C virus drug, faldaprevir, using a rat hepatocyte model (HepatoPac).
    Ramsden D; Tweedie DJ; St George R; Chen LZ; Li Y
    Drug Metab Dispos; 2014 Mar; 42(3):407-14. PubMed ID: 24366905
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Quantitative prediction of human intestinal glucuronidation effects on intestinal availability of UDP-glucuronosyltransferase substrates using in vitro data.
    Nakamori F; Naritomi Y; Hosoya K; Moriguchi H; Tetsuka K; Furukawa T; Kadono K; Yamano K; Terashita S; Teramura T
    Drug Metab Dispos; 2012 Sep; 40(9):1771-7. PubMed ID: 22685216
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Characterization of the binding of drugs to human intestinal fatty acid binding protein (IFABP): potential role of IFABP as an alternative to albumin for in vitro-in vivo extrapolation of drug kinetic parameters.
    Rowland A; Knights KM; Mackenzie PI; Miners JO
    Drug Metab Dispos; 2009 Jul; 37(7):1395-403. PubMed ID: 19398502
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mechanistic insights from comparing intrinsic clearance values between human liver microsomes and hepatocytes to guide drug design.
    Di L; Keefer C; Scott DO; Strelevitz TJ; Chang G; Bi YA; Lai Y; Duckworth J; Fenner K; Troutman MD; Obach RS
    Eur J Med Chem; 2012 Nov; 57():441-8. PubMed ID: 22840492
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of rifampin and nelfinavir on the metabolism of methadone and buprenorphine in primary cultures of human hepatocytes.
    Moody DE; Fang WB; Lin SN; Weyant DM; Strom SC; Omiecinski CJ
    Drug Metab Dispos; 2009 Dec; 37(12):2323-9. PubMed ID: 19773542
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of albumin on human liver microsomal and recombinant CYP1A2 activities: impact on in vitro-in vivo extrapolation of drug clearance.
    Wattanachai N; Tassaneeyakul W; Rowland A; Elliot DJ; Bowalgaha K; Knights KM; Miners JO
    Drug Metab Dispos; 2012 May; 40(5):982-9. PubMed ID: 22331994
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In Vitro-In Vivo Inaccuracy: The CYP3A4 Anomaly.
    Bowman CM; Benet LZ
    Drug Metab Dispos; 2019 Dec; 47(12):1368-1371. PubMed ID: 31551322
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.